UNION CITY, Calif., May 02, 2005 (BUSINESS WIRE) -- Questcor Pharmaceuticals, Inc. (AMEX:QSC), a specialty
pharmaceutical company, announced today that Craig Chambliss has
joined the company as Vice President of Sales & Marketing.
"We are excited to have Craig join Questcor. His experience and
abilities will be a welcome addition to the Questcor team. Craig's
specialty pharmaceutical background, experience with Central Nervous
System products, and skills in sales, marketing, and management are an
ideal fit for Questcor," explained Jim Fares, Questcor's President and
Mr. Chambliss has 14 years of experience in the specialty
pharmaceutical and drug delivery industries. Mr. Chambliss joins
Questcor from Xcel Pharmaceuticals where he was Vice President of
Sales & Marketing. He joined Xcel, a private start up company, in
2001. He was a key contributor to Xcel's rapid sales growth, product
acquisitions, and development programs. Previously, Mr. Chambliss was
the Director of Business Development for Elan Corporation, where he
was responsible for developing and optimizing Elan's Central Nervous
System (CNS) product portfolio. Before joining Elan in early 2000, Mr.
Chambliss worked for Ther-Rx Corporation as Director of Marketing.
Prior to Ther-Rx, Craig spent five years with Alza Pharmaceuticals in
various sales and marketing management roles and began his career in
sales at Bristol-Myers Squibb. Mr. Chambliss received his bachelor's
degrees from Southwest Missouri State University in Finance and
Mr. Chambliss will be responsible for Questcor's sales and
marketing efforts and ensuring the commercial success of the company's
new CNS focus.
Questcor Pharmaceuticals, Inc.(R) (AMEX:QSC) is a specialty
pharmaceutical company that develops, acquires, markets and sells
brand name prescription drugs for neurological and other uses through
a U.S. direct sales force and international distributors. Questcor
currently markets four products in the U.S.: H.P. Acthar(R) Gel
(repository corticotropin injection), an injectable drug that is
commonly used for certain neurological conditions; Nascobal(R), the
only prescription nasal gel formulation of Cyanocobalamin USP (Vitamin
B12), that is approved for patients with B12 deficiency caused by
malabsorptive disorders resulting from structural or functional
damage, such as bariatric surgery, Crohn's disease and certain
neurological conditions; Ethamolin(R) (Ethanolamine Oleate), an
injectable drug used to treat enlarged weakened blood vessels at the
entrance to the stomach that have recently bled, known as esophageal
varices; and Glofil-125(R), which is an injectable agent that assesses
how well the kidney is working by measuring glomerular filtration
rate, or kidney function.
Note: Except for the historical information contained herein, this
press release contains forward-looking statements that involve risks
and uncertainties. Such statements are subject to certain factors,
which may cause Questcor's results to differ from those reported
herein. Factors that may cause such differences include, but are not
limited to, Questcor's ability to accurately forecast and create the
demand for each of its products, the gross margins achieved from the
sale of those products, Questcor's ability to enforce its exchange
policy, the accuracy of the prescription data purchased from
independent third parties by Questcor, the sell through by Questcor's
distributors, the inventories carried by Questcor's distributors, and
the expenses and other cash needs for the upcoming periods, Questcor's
ability to obtain finished goods from its sole source contract
manufacturers on a timely basis if at all, Questcor's need for
additional funding, uncertainties regarding Questcor's intellectual
property and other research, development, marketing and regulatory
risks, and, to the ability of Questcor to implement its strategy and
acquire products and, if acquired, to market them successfully as well
as the risks discussed in Questcor's report on Form 10-K for the
calendar year ended December 31, 2004 and other documents filed with
the Securities and Exchange Commission. The risk factors and other
information contained in these documents should be considered in
evaluating Questcor's prospects and future financial performance.
Questcor undertakes no obligation to publicly release the result
of any revisions to these forward-looking statements, which may be
made to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events.
SOURCE: Questcor Pharmaceuticals, Inc.
Questcor Pharmaceuticals, Inc.
James L. Fares, 510-400-0700